TABLE 3.

List of COVID-19 marketed vaccines: manufacturers, trade names, platforms and existing status of approval for usage in various countries are mentioned in the representative table.

Inventor	Name of vaccine	Platform	Status for emergency use
Moderna	mRNA-1273	mRNA encapsulated in lipid nanoparticle	Approved in Switzerland. Emergency use in U.S., U.K., E.U., others.
Bharat Biotech	Covaxin, BBV152 A, B, C	Whole virion Inactivated SARS-CoV-2 vaccine + adjuvant	Emergency use in India.
Pfizer/BioNtech	Comirnaty, tozinameran, BNT162b2	mRNA encapsulated in lipid nanoparticle	Emergency use in U.S., E.U. etc., Approved in several countries.
OXFORD AstraZeneca	AZD1222 (Covishield in India)	Attenuated adenoviral vector (non-replicating) from chimpanzee ChAd	Emergency use in U.K., E.U., India, and other countries.
Sinovac	CoronaVac, PiCoVacc	Inactivated coronavirus- Done using chemical beta-propiolactone	Approved in China, Emergency use in Brazil, Singapore, Malaysia, and Philippines
Gamaleya	Sputnik V, Gam-COVID-Vac	Viral 2 vector-based vaccine- rAd26 vector and rAd5 vector	Early use in Russia, Emergency use in other countries.
Sinopharm	BBIBP-CorV	Inactivated SARS-CoV-2 vaccine (Vero cell)	Approved in China, U.A.E., Bahrain, Emergency use in Egypt, other countries.
CanSino	Convidecia, Ad5-nCoV	Adenovirus based viral vector (Ad5)- Non-Replicating	Emergency use in China and Mexico
Johnson and Johnson	Ad26.COV2.S	Adenovirus based viral vector (Ad26)- Non-Replicating	Applied for emergency use authorization in United States
Vector Institute	EpiVacCorona	Chemically synthesized peptide antigens of SARS-CoV-2 proteins	Early use in Russia.
Novavax	NVX-CoV2373	S Protein adjuvanted with recombinant novavax protein	Early use in United Kingdom and Australia